UNSPSC 51384602: Aminophenazone or aminopyrine

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H17N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01704YP3MO, chemically known as 1,5-dimethyl-2-phenyl-4-aminopyrazoline but generally known as aminophenazone, which bears US NIH Compound Identifier 2151. Aminophenazone most often comes in base, 2,5-dihydroxybenzoate, cyclamate, and salicylate forms.

UNSPSC 51384602 Aminophenazone or aminopyrine is a Commodity code that captures pharmaceutical products sourced through state and local health and human services procurement. Recent activity shows state and local governments are buying naloxone (opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements, not aminophenazone or aminopyrine specifically. The code's nominal scope does not align with what is actually being solicited under it in current state and local opportunities.

Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, response due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives with quarterly deliveries to the Seminole County Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (Solicitation S1070000015802, response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013, posted April 3, 2026) to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program for the state's pharmacy benefit program. Activity appears concentrated among state agencies and county health departments in Florida, Minnesota, and Texas, with cooperative purchasing arrangements serving multiple jurisdictions.